Transcenta Holding Ltd
Transcenta Holding Ltd is a biotechnology company focused on the research, development, and commercialization of innovative therapies in the healthcare sector.
Business. Transcenta Holding Ltd (6628.HK) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Transcenta Holding Ltd (6628.HK) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Transcenta Holding Ltd has a basic and diluted share count of 452,858,499 shares outstanding, indicating no dilution from potential share-based compensation or convertible instruments. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available for Transcenta, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Transcenta's operations are diversified or concentrated in specific regions or product lines.
Growth trajectory data is also absent, with no outlook provided for the current or next fiscal year. The lack of revenue history and forward-looking guidance limits the ability to assess the company's growth potential or market expansion plans.
Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilutive events such as share-based compensation or convertible instruments. However, the absence of financial data means that any adjustments or valuation signals from custom valuations are not available for further analysis.
Recent events, including filings or transcripts, are not disclosed in the available data. This limits the ability to assess management commentary, strategic shifts, or regulatory developments that may impact the company's operations or valuation.
- Transcenta Holding Ltd has no dilution from basic to diluted shares outstanding.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
- Profitability and return metrics are not available, making it difficult to benchmark against industry standards.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into operational diversification.
- Growth trajectory and forward-looking guidance are absent, reducing clarity on future performance expectations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥7.4M, −34,0% YoY; Operating income +28,8% YoY.
- ▍Revenue ¥7.4M, −34,0% YoY
- ▍Operating income +28,8% YoY
- ▍Net income +29,8% YoY
- ▍Net margin -2740.1%
Revenue ¥53.8M, −47,1% YoY; Operating income −22,0% YoY.
- ▍Revenue ¥53.8M, −47,1% YoY
- ▍Operating income −22,0% YoY
- ▍Net income −13,7% YoY
- ▍Free cash flow −13,6% YoY
- ▍Net margin -859.0%
Revenue ¥101.9M, +102,8% YoY; Operating income +78,4% YoY.
- ▍Revenue ¥101.9M, +102,8% YoY
- ▍Operating income +78,4% YoY
- ▍Net income +76,3% YoY
- ▍Free cash flow +78,5% YoY
- ▍Net margin -399.2%
Revenue ¥50.2M; Operating income -¥1.70B.
- ▍Revenue ¥50.2M
- ▍Operating income -¥1.70B
- ▍Net margin -3414.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,70 |
| Revenue | —no estimate | —no estimate | 14,0M CNY |
| Operating income | —no estimate | —no estimate | -281,0M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Transcenta Holding Ltd Market data — financials · 2026-05-27
- Transcenta Holding Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Xueming QianChief Executive Officer, Executive Director